[go: up one dir, main page]

GB202405758D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB202405758D0
GB202405758D0 GBGB2405758.0A GB202405758A GB202405758D0 GB 202405758 D0 GB202405758 D0 GB 202405758D0 GB 202405758 A GB202405758 A GB 202405758A GB 202405758 D0 GB202405758 D0 GB 202405758D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2405758.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB2405758.0A priority Critical patent/GB202405758D0/en
Publication of GB202405758D0 publication Critical patent/GB202405758D0/en
Priority to PCT/EP2025/061121 priority patent/WO2025224196A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2405758.0A 2024-04-24 2024-04-24 Compounds Pending GB202405758D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2405758.0A GB202405758D0 (en) 2024-04-24 2024-04-24 Compounds
PCT/EP2025/061121 WO2025224196A1 (en) 2024-04-24 2025-04-23 Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2405758.0A GB202405758D0 (en) 2024-04-24 2024-04-24 Compounds

Publications (1)

Publication Number Publication Date
GB202405758D0 true GB202405758D0 (en) 2024-06-05

Family

ID=91275270

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2405758.0A Pending GB202405758D0 (en) 2024-04-24 2024-04-24 Compounds

Country Status (2)

Country Link
GB (1) GB202405758D0 (en)
WO (1) WO2025224196A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
GB0404574D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
WO2007039752A1 (en) 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
CL2008001334A1 (en) 2007-05-08 2008-09-22 Genentech Inc ANTI-MUC16 ANTIBODY DESIGNED WITH CISTEINE; CONJUGADO THAT UNDERSTANDS IT; METHOD OF PRODUCTION; PHARMACEUTICAL FORMULATION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER.
AU2008312457B2 (en) 2007-10-19 2014-04-17 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
BR112014027143B1 (en) 2012-04-30 2020-06-09 Medimmune Ltd pyrrolobenzodiazepines
GB201900929D0 (en) * 2019-01-23 2019-03-13 King S College London Nf-kappa b inhibitors

Also Published As

Publication number Publication date
WO2025224196A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
GB202501331D0 (en) Compounds
GB202501329D0 (en) Compounds
GB202500897D0 (en) Compounds
GB202500755D0 (en) Compounds
GB202500764D0 (en) Compounds
GB202500762D0 (en) Compounds
GB202500761D0 (en) Compounds
GB202500496D0 (en) Compounds
GB202500342D0 (en) Compounds
GB202418679D0 (en) Compounds
GB202417520D0 (en) Compounds
GB202417516D0 (en) Compounds
GB202416725D0 (en) Compounds
GB202416563D0 (en) Compounds
GB202416444D0 (en) Compounds
GB202415958D0 (en) Compounds
GB202415868D0 (en) Compounds
GB202412967D0 (en) Compounds
GB202412846D0 (en) Compounds
GB202412852D0 (en) Compounds
GB202412861D0 (en) Compounds
GB202412857D0 (en) Compounds
GB202412850D0 (en) Compounds
GB202412842D0 (en) Compounds
GB202412849D0 (en) Compounds